Emily Boja, Ph.D.

Program Director

Emily Boja

Dr. Boja provides leadership in managing scientific portfolio of the Clinial Proteomic Tumor Analysis Consortium (CPTAC) program involving large-scale, deep and complex proteogenomic studies of biological and clinical specimens. The goals are to better understand tumor biology, predict drug response to therapy, and reveal the mechanisms of drug resistance, all of which are central to the mission of the CPTAC program. She also oversees the analytical, informatics and regulatory aspects of molecular technologies, platforms and tools via interactions with the U.S. Food and Drug Administration (FDA) and the American Association of Clinical Chemistry (AACC), for example, applying targeted proteomic assays in the clinic and precisionFDA-NCI-CPTAC Multi-Omics Enabled Sample Mislabeling Correction Challenge.  Prior to the National Cancer Institute, Dr. Boja served as a Staff Scientist and Lead of Proteomics at the Laboratory of Cardiac Energetics, and a Research Fellow at the Laboratory of Biophysical Chemistry, National Heart, Lung and BIood Institute (intramural programs), NIH.  Her expertise originates from her structural biology and systems biology-focused research on key enzymes and pathways involved in one-carbon metabolism, focusing on the role of serine hydroxymethyl transferase on serine synthesis pathways and the impact of its dysregulation on cancer, and later comprehensive proteomic and phosphoproteomic analyses of mitochondria that play a role in cardiac energetics through the integration of genomics and proteomics data. Dr. Boja holds a Ph.D. degree in Biochemistry and Molecular Biology (1999) from the Medical College of Virginia, Virginia Commonwealth University.

See publication record at: https://www.ncbi.nlm.nih.gov/myncbi/collections/57223470/